E
Champions Oncology, Inc.
CSBR
$5.02
-$0.04-0.79%
E
Sell
12/14/2023Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to E+ from D- on 12/14/2023 due to a decline in the volatility index, solvency index and growth index. Debt to equity increased from 0.65 to 13.71, total revenue declined 7.87% from $12.56M to $11.57M, and the quick ratio declined from 0.68 to 0.63.
Champions Oncology, Inc. (CSBR) was downgraded to E+ from D- on 12/14/2023 due to a decline in the volatility index, solvency index and growth index. Debt to equity increased from 0.65 to 13.71, total revenue declined 7.87% from $12.56M to $11.57M, and the quick ratio declined from 0.68 to 0.63.
D
Sell
9/18/2023Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 9/18/2023 due to a noticeable decline in the efficiency index, solvency index and growth index. Operating cash flow declined 476.73% from -$692 to -$3.99M, debt to equity increased from 0.26 to 0.65, and EBIT declined 48.89% from -$1.71M to -$2.55M.
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 9/18/2023 due to a noticeable decline in the efficiency index, solvency index and growth index. Operating cash flow declined 476.73% from -$692 to -$3.99M, debt to equity increased from 0.26 to 0.65, and EBIT declined 48.89% from -$1.71M to -$2.55M.
D
Sell
8/9/2023Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 8/9/2023 due to an increase in the volatility index, total return index and valuation index.
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 8/9/2023 due to an increase in the volatility index, total return index and valuation index.
D
Sell
7/25/2023Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 7/25/2023 due to a decline in the efficiency index and solvency index. Debt to equity increased from 0.17 to 0.26, total capital declined 16.93% from $15.93M to $13.24M, and the quick ratio declined from 0.95 to 0.83.
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 7/25/2023 due to a decline in the efficiency index and solvency index. Debt to equity increased from 0.17 to 0.26, total capital declined 16.93% from $15.93M to $13.24M, and the quick ratio declined from 0.95 to 0.83.
D
Sell
6/14/2023Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 6/14/2023 due to an increase in the total return index and volatility index.
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 6/14/2023 due to an increase in the total return index and volatility index.
D
Sell
3/17/2023Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 3/17/2023 due to a noticeable decline in the total return index, efficiency index and volatility index. Net income declined 15,143.75% from -$16 to -$2.44M, and total capital declined 12.16% from $18.14M to $15.93M.
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 3/17/2023 due to a noticeable decline in the total return index, efficiency index and volatility index. Net income declined 15,143.75% from -$16 to -$2.44M, and total capital declined 12.16% from $18.14M to $15.93M.
D
Sell
12/14/2022Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 12/14/2022 due to a significant decline in the growth index, volatility index and efficiency index. Total capital declined 0.4% from $18.21M to $18.14M.
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 12/14/2022 due to a significant decline in the growth index, volatility index and efficiency index. Total capital declined 0.4% from $18.21M to $18.14M.
D
Sell
10/28/2022Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D+ from C- on 10/28/2022 due to a decline in the volatility index.
Champions Oncology, Inc. (CSBR) was downgraded to D+ from C- on 10/28/2022 due to a decline in the volatility index.
C
Hold
9/19/2022Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to C- from D+ on 9/19/2022 due to an increase in the volatility index and total return index.
Champions Oncology, Inc. (CSBR) was upgraded to C- from D+ on 9/19/2022 due to an increase in the volatility index and total return index.
D
Sell
9/13/2022Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 9/13/2022 due to a significant increase in the growth index, total return index and solvency index. EBIT increased 8.68% from -$311 to -$284, earnings per share increased from -$0.0255 to -$0.0236, and total revenue increased 6.74% from $12.88M to $13.75M.
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 9/13/2022 due to a significant increase in the growth index, total return index and solvency index. EBIT increased 8.68% from -$311 to -$284, earnings per share increased from -$0.0255 to -$0.0236, and total revenue increased 6.74% from $12.88M to $13.75M.
D
Sell
7/25/2022Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 7/25/2022 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.05 to -$0.0255, EBIT declined 137.47% from $830 to -$311, and operating cash flow declined 81.3% from $4.26M to $796.
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 7/25/2022 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.05 to -$0.0255, EBIT declined 137.47% from $830 to -$311, and operating cash flow declined 81.3% from $4.26M to $796.
D
Sell
12/2/2021Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D+ from C- on 12/2/2021 due to a decline in the volatility index and solvency index.
Champions Oncology, Inc. (CSBR) was downgraded to D+ from C- on 12/2/2021 due to a decline in the volatility index and solvency index.
C
Hold
9/14/2021Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to C- from D on 9/14/2021 due to a major increase in the efficiency index, growth index and solvency index. Operating cash flow increased 110.91% from -$1.98M to $216, earnings per share increased from -$0.0432 to -$0.0128, and net income increased 62.11% from -$454 to -$172.
Champions Oncology, Inc. (CSBR) was upgraded to C- from D on 9/14/2021 due to a major increase in the efficiency index, growth index and solvency index. Operating cash flow increased 110.91% from -$1.98M to $216, earnings per share increased from -$0.0432 to -$0.0128, and net income increased 62.11% from -$454 to -$172.
D
Sell
3/25/2020Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D from C- on 3/25/2020 due to a significant decline in the efficiency index, total return index and growth index. Operating cash flow declined 22.5% from $360 to $279.
Champions Oncology, Inc. (CSBR) was downgraded to D from C- on 3/25/2020 due to a significant decline in the efficiency index, total return index and growth index. Operating cash flow declined 22.5% from $360 to $279.
C
Hold
8/20/2019Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to C- from C on 8/20/2019 due to a decline in the total return index.
Champions Oncology, Inc. (CSBR) was downgraded to C- from C on 8/20/2019 due to a decline in the total return index.
C
Hold
8/5/2019Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to C from C- on 8/5/2019 due to a noticeable increase in the efficiency index, growth index and solvency index. Debt to equity declined from 0.1 to 0.01, EBIT increased 68.65% from -$370 to -$116, and net income increased 31.44% from -$369 to -$253.
Champions Oncology, Inc. (CSBR) was upgraded to C from C- on 8/5/2019 due to a noticeable increase in the efficiency index, growth index and solvency index. Debt to equity declined from 0.1 to 0.01, EBIT increased 68.65% from -$370 to -$116, and net income increased 31.44% from -$369 to -$253.
C
Hold
5/7/2019Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to C- from D+ on 5/7/2019 due to an increase in the total return index, valuation index and volatility index.
Champions Oncology, Inc. (CSBR) was upgraded to C- from D+ on 5/7/2019 due to an increase in the total return index, valuation index and volatility index.
D
Sell
3/29/2019Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D+ from C- on 3/29/2019 due to a large decline in the total return index, efficiency index and volatility index. Net income declined 238.2% from $267 to -$369.
Champions Oncology, Inc. (CSBR) was downgraded to D+ from C- on 3/29/2019 due to a large decline in the total return index, efficiency index and volatility index. Net income declined 238.2% from $267 to -$369.
C
Hold
12/18/2018Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to C- from C on 12/18/2018 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 80.95% from $336 to $64, earnings per share declined from $0.04 to $0.02, and EBIT declined 42.83% from $481 to $275.
Champions Oncology, Inc. (CSBR) was downgraded to C- from C on 12/18/2018 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 80.95% from $336 to $64, earnings per share declined from $0.04 to $0.02, and EBIT declined 42.83% from $481 to $275.
C
Hold
9/17/2018Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to C from D on 9/17/2018 due to a significant increase in the total return index, efficiency index and growth index. Operating cash flow increased 3,633.33% from $9 to $336, total capital increased 1,871.11% from $45 to $887, and EBIT increased 180.3% from -$599 to $481.
Champions Oncology, Inc. (CSBR) was upgraded to C from D on 9/17/2018 due to a significant increase in the total return index, efficiency index and growth index. Operating cash flow increased 3,633.33% from $9 to $336, total capital increased 1,871.11% from $45 to $887, and EBIT increased 180.3% from -$599 to $481.
D
Sell
8/1/2017Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 8/1/2017 due to an increase in the growth index and volatility index. Operating cash flow increased 158.27% from -$683 to $398, and total revenue increased 4.35% from $3.57M to $3.72M.
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 8/1/2017 due to an increase in the growth index and volatility index. Operating cash flow increased 158.27% from -$683 to $398, and total revenue increased 4.35% from $3.57M to $3.72M.
D
Sell
6/28/2017Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 6/28/2017 due to a noticeable decline in the growth index, solvency index and valuation index. Operating cash flow declined 488.79% from -$116 to -$683, EBIT declined 184.18% from -$493 to -$1.4M, and earnings per share declined from -$0.046 to -$0.1285.
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 6/28/2017 due to a noticeable decline in the growth index, solvency index and valuation index. Operating cash flow declined 488.79% from -$116 to -$683, EBIT declined 184.18% from -$493 to -$1.4M, and earnings per share declined from -$0.046 to -$0.1285.
D
Sell
9/16/2016Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 9/16/2016 due to an increase in the growth index, valuation index and solvency index. Debt to equity declined from 0.1 to 0.01, the quick ratio increased from 0.73 to 1.38, and total revenue increased 29.36% from $2.84M to $3.67M.
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 9/16/2016 due to an increase in the growth index, valuation index and solvency index. Debt to equity declined from 0.1 to 0.01, the quick ratio increased from 0.73 to 1.38, and total revenue increased 29.36% from $2.84M to $3.67M.
D
Sell
8/5/2016Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 8/5/2016 due to a decline in the growth index, solvency index and total return index. Debt to equity increased from 0.01 to 0.1, the quick ratio declined from 1.16 to 0.73, and earnings per share declined from -$0.28 to -$0.3033.
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 8/5/2016 due to a decline in the growth index, solvency index and total return index. Debt to equity increased from 0.01 to 0.1, the quick ratio declined from 1.16 to 0.73, and earnings per share declined from -$0.28 to -$0.3033.
D
Sell
3/11/2016Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 3/11/2016 due to a substantial decline in the volatility index and total return index.
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 3/11/2016 due to a substantial decline in the volatility index and total return index.
D
Sell
12/17/2015Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 12/17/2015 due to a large increase in the growth index and solvency index. Total revenue increased 5.28% from $2.82M to $2.97M, and operating cash flow increased 1.61% from -$2.54M to -$2.58M.
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 12/17/2015 due to a large increase in the growth index and solvency index. Total revenue increased 5.28% from $2.82M to $2.97M, and operating cash flow increased 1.61% from -$2.54M to -$2.58M.
D
Sell
12/8/2015Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 12/8/2015 due to a substantial decline in the volatility index and total return index.
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 12/8/2015 due to a substantial decline in the volatility index and total return index.
D
Sell
9/11/2015Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 9/11/2015 due to a noticeable increase in the volatility index, growth index and total return index. Operating cash flow increased 26.64% from -$2.01M to -$2.54M, and EBIT increased 20.51% from -$2.4M to -$2.9M.
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 9/11/2015 due to a noticeable increase in the volatility index, growth index and total return index. Operating cash flow increased 26.64% from -$2.01M to -$2.54M, and EBIT increased 20.51% from -$2.4M to -$2.9M.
D
Sell
8/3/2015Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 8/3/2015 due to a decline in the valuation index, efficiency index and total return index. Total capital declined 475.89% from -$2.14M to $8.06M.
Champions Oncology, Inc. (CSBR) was downgraded to D from D+ on 8/3/2015 due to a decline in the valuation index, efficiency index and total return index. Total capital declined 475.89% from -$2.14M to $8.06M.
D
Sell
5/26/2015Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 5/26/2015 due to a noticeable increase in the total return index and volatility index.
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 5/26/2015 due to a noticeable increase in the total return index and volatility index.
D
Sell
3/20/2015Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D from C on 3/20/2015 due to a significant decline in the efficiency index, volatility index and total return index. Net income declined 8.51% from -$3.08M to -$2.82M.
Champions Oncology, Inc. (CSBR) was downgraded to D from C on 3/20/2015 due to a significant decline in the efficiency index, volatility index and total return index. Net income declined 8.51% from -$3.08M to -$2.82M.
C
Hold
12/18/2014Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to C from D+ on 12/18/2014 due to a significant increase in the efficiency index and valuation index.
Champions Oncology, Inc. (CSBR) was upgraded to C from D+ on 12/18/2014 due to a significant increase in the efficiency index and valuation index.
D
Sell
9/17/2014Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 9/17/2014 due to an increase in the volatility index.
Champions Oncology, Inc. (CSBR) was upgraded to D+ from D on 9/17/2014 due to an increase in the volatility index.
D
Sell
6/30/2014Upgraded
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 6/30/2014 due to a large increase in the volatility index.
Champions Oncology, Inc. (CSBR) was upgraded to D from D- on 6/30/2014 due to a large increase in the volatility index.
D
Sell
5/29/2014Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 5/29/2014 due to a significant decline in the volatility index.
Champions Oncology, Inc. (CSBR) was downgraded to D- from D on 5/29/2014 due to a significant decline in the volatility index.
D
Sell
3/18/2014Downgrade
Champions Oncology, Inc. (CSBR) was downgraded to D from C on 3/18/2014 due to a significant decline in the efficiency index. Total capital declined 135.2% from -$12.74M to $4.49M, and net income declined 75.24% from -$2.32M to -$574.
Champions Oncology, Inc. (CSBR) was downgraded to D from C on 3/18/2014 due to a significant decline in the efficiency index. Total capital declined 135.2% from -$12.74M to $4.49M, and net income declined 75.24% from -$2.32M to -$574.
NASDAQ
04/26/2024 3:59PM Eastern
Quotes delayed
